Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 19/20 | 0.49 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.35 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2305156 | 0.85 | SCN9A (0.49) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL15313059 | 0.85 | SCN9A (0.49) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL2579940 | 0.85 | SCN9A (0.50) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL2305161 | 0.83 | SCN9A (0.42) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3332268 | 0.81 | SCN9A (0.48) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL2306996 | 0.81 | SCN9A (0.41) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL2305420 | 0.81 | SCN9A (0.40) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL2583417 | 0.79 | ALDH1A1 (0.38) | SCN9AALDH1A1GAA | |
| SCHEMBL281330 | 0.79 | SCN9A (0.57) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL15312953 | 0.79 | SCN9A (0.57) | SCN9ASCN7ASCN5ASCN2ASCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269788-A1 | SPIRO-OXINDOLE-DERIVATIVES AS SODIUM CHANNEL BLOCKERS | XENON PHARMACEUTICALS INC. (CA) | 2011-11-03 | — | — | US | claimed |
| US-20110269788-A1 | SPIRO-OXINDOLE-DERIVATIVES AS SODIUM CHANNEL BLOCKERS | XENON PHARMACEUTICALS INC. (CA) | 2011-11-03 | — | — | US | disclosed |
| US-20110269788-A1 | SPIRO-OXINDOLE-DERIVATIVES AS SODIUM CHANNEL BLOCKERS | XENON PHARMACEUTICALS INC. (CA) | 2011-11-03 | — | — | US | disclosed |
| US-20110269788-A1 | SPIRO-OXINDOLE-DERIVATIVES AS SODIUM CHANNEL BLOCKERS | XENON PHARMACEUTICALS INC. (CA) | 2011-11-03 | — | — | US | disclosed |
| WO-2010078307-A1 | SPIRO-OXINDOLE-DERIVATIVES AS SODIUM CHANNEL BLOCKERS | XENON PHARMACEUTICALS INC. (CA) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269788-A1 | SPIRO-OXINDOLE-DERIVATIVES AS SODIUM CHANNEL BLOCKERS | SCN3A, SCN1B, SCN2B | SCN9A 27/4885SCN7A 30/4885SCN5A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.